Nantais-Smith Leanne, Kadrofske Mark
College of Nursing, Wayne State University, 5557 Cass Ave, 240 Cohn, Detroit, MI 48202, USA.
J Perinat Neonatal Nurs. 2015 Jan-Mar;29(1):69-80. doi: 10.1097/JPN.0000000000000082.
Necrotizing enterocolitis is an acute inflammatory disease, which primarily affects preterm infants, and is a leading cause of morbidity and mortality in the neonatal intensive care unit. Unfortunately, necrotizing enterocolitis can be difficult to distinguish from other diseases and clinical conditions especially during the early course of the disease. This diagnostic uncertainty is particularly relevant to clinical evaluation and medical management and potentially leads to unnecessary and extended periods of cessation of enteral feedings and prolonged courses of parenteral nutrition and antibiotics. Biomarkers are molecular indicators of a disease process, diagnosis, prognosis and can be used to monitor the effects of disease management. Historically, there has been a paucity of reliable and robust biomarkers for necrotizing enterocolitis. However, several studies have recently identified promising biomarkers. Noninvasive samples for biomarker measurement are preferred and may have certain advantages in the preterm infant. In this review article, we focus on recent exciting and promising discoveries in noninvasive biomarkers for necrotizing enterocolitis.
坏死性小肠结肠炎是一种急性炎症性疾病,主要影响早产儿,是新生儿重症监护病房发病和死亡的主要原因。不幸的是,坏死性小肠结肠炎可能很难与其他疾病和临床状况区分开来,尤其是在疾病早期。这种诊断上的不确定性与临床评估和医疗管理特别相关,并可能导致不必要的、延长的肠内喂养中断以及肠外营养和抗生素疗程延长。生物标志物是疾病过程、诊断、预后的分子指标,可用于监测疾病管理的效果。历史上,坏死性小肠结肠炎缺乏可靠且强大的生物标志物。然而,最近的几项研究已经确定了有前景的生物标志物。用于生物标志物测量的非侵入性样本是首选,并且在早产儿中可能具有某些优势。在这篇综述文章中,我们重点关注坏死性小肠结肠炎非侵入性生物标志物方面最近令人兴奋且有前景的发现。